1. Home
  2. KNDI vs MDXH Comparison

KNDI vs MDXH Comparison

Compare KNDI & MDXH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

KNDI

Kandi Technologies Group Inc

HOLD

Current Price

$0.85

Market Cap

67.8M

ML Signal

HOLD

Logo MDxHealth SA

MDXH

MDxHealth SA

HOLD

Current Price

$3.45

Market Cap

167.8M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
KNDI
MDXH
Founded
2002
2003
Country
China
Belgium
Employees
N/A
N/A
Industry
Auto Manufacturing
Sector
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
67.8M
167.8M
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
KNDI
MDXH
Price
$0.85
$3.45
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
$7.67
AVG Volume (30 Days)
250.8K
117.5K
Earning Date
03-13-2026
11-12-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$104,035,613.00
$103,069,000.00
Revenue This Year
N/A
$23.34
Revenue Next Year
N/A
$22.98
P/E Ratio
N/A
N/A
Revenue Growth
N/A
21.68
52 Week Low
$0.78
$1.35
52 Week High
$1.81
$5.33

Technical Indicators

Market Signals
Indicator
KNDI
MDXH
Relative Strength Index (RSI) 41.80 47.72
Support Level $0.78 $3.20
Resistance Level $0.88 $3.58
Average True Range (ATR) 0.08 0.19
MACD -0.00 0.05
Stochastic Oscillator 20.91 70.00

Price Performance

Historical Comparison
KNDI
MDXH

About KNDI Kandi Technologies Group Inc

Kandi Technologies Group Inc is engaged in developing, manufacturing, and commercializing fully electric vehicle products and related technologies. Its products mainly consist of EV parts, EV products, and off-road vehicles, including All-Terrain Vehicles (ATVs), UTVs, go-karts, electric scooters, electric self-balancing scooters, and associated parts, and Lithium-ion cells, etc. The company generates maximum revenue from the sale of Off-road vehicles and associated parts. Geographically, it derives maximum revenue from the United States and other countries, followed by China.

About MDXH MDxHealth SA

MDxHealth SA is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. Its tests are based on proprietary genomic, epigenetic, and other molecular technologies and assist physicians with the diagnosis of urologic cancers, the prognosis of recurrence risk, and the prediction of response to a specific therapy. It derives revenues from clinical laboratory service testing or the out-licensing of the company's patented DNA methylation platform and biomarkers. Geographically, it derives revenue from the United States of America (USA) and Europe.

Share on Social Networks: